1
Nandini Katre, Michael J Knauf: Solubilization of proteins for pharmaceutical compositions using polymer conjugation. Cetus Corporation, Albert P Halluin, Janet E Hasak, August 23, 1988: US04766106 (299 worldwide citation)

A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not r ...


2
Nandini Katre, Robert F Halenbeck, Robert J Goodson, Peter C McCabe, Michael J Knauf: Interleukin-2 muteins and polymer conjugation thereof. Cetus Oncology Corporation, Philip L McGarrigle, Janet E Hasak, April 27, 1993: US05206344 (225 worldwide citation)

Muteins of IL-2 in which one of the amino acids of the mature native sequence of IL-2 is replaced by a cysteine residue are prepared and conjugated through the replaced cysteine residue to a polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols, wherein said homopolymers ...


3
Paula J Shadle, Kirston E Koths, Margaret Moreland, Nandini Katre: Conjugation of polymer to colony stimulating factor-1. Cetus Corporation, Albert P Halluin, July 11, 1989: US04847325 (215 worldwide citation)

A biologically active CSF-1 protein is selectively conjugated via certain amino acid residues or carbohydrate moieties to a water-soluble polymer selected from polyethylene glycol or polypropylene glycol homopolymers, polyoxyethylated polyols, or polyvinyl alcohol. The resulting conjugated CSF-1 is ...


4
Nandini Katre, Michael J Knauf: Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation. Cetus Corporation, Janet E Hasak, Philip L McGarrigle, Albert P Halluin, April 17, 1990: US04917888 (133 worldwide citation)

A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not r ...


5
Danute E Nitecki, Nandini Katre, Robert J Goodson, Lois Aldwin: Preparation of a polymer/interleukin-2 conjugate. Cetus Corporation, Philip L McGarrigle, Albert P Halluin, February 20, 1990: US04902502 (129 worldwide citation)

The present invention is a process for preparing a pharmaceutical composition comprising a biologically active conjugated protein. It comprises a polyethylene glycol or a polyoxyethylated polyol conjugated to IL-2. This protein is conjugated to reduce its immunogenicity, and increase it solubility, ...


6
Paula J Shadle, Kirston E Koths, Margaret Moreland, Nandini Katre, Walter J Laird, Lois Aldwin, Danute E Nitecki, John D Young: Conjugation of polymer to colony stimulating factor-1. Cetus Corporation, Philip L McGarrigle, Jane R McLaughlin, Albert P Halluin, October 6, 1992: US05153265 (92 worldwide citation)

A biologically active CSF-1 protein is selectively conjugated via certain amino acid residues or carbohydrate moieties to a water-soluble polymer selected from polyethylene glycol or polypropylene glycol homopolymers, polyoxyethylated polyols, or polyvinyl alcohol. The resulting conjugated CSF-1 is ...


7
Danute E Nitecki, Nandini Katre, Robert J Goodson, Lois Aldwin: Preparation of a polymer/interleukin-2 conjugate. Cetus Corporation, Philip L McGarrigle, February 18, 1992: US05089261 (87 worldwide citation)

The present invention is a process for preparing a pharmaceutical composition comprising a biologically active conjugated protein. It comprises a polyethylene glycol or a polyoxyethylated polyol conjugated to IL-2. This protein is conjugated to reduce its immunogenicity, and increase its solubility, ...


8
Nandini Katre, Michael J Knauf: Succinylated interleukin-2 for pharmaceutical compositions. Cetus Corporation, Janet E Hasak, Albert P Halluin, June 5, 1990: US04931544 (31 worldwide citation)

A pharmaceutical composition is prepared wherein biologically active conjugated interleukin-2 is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated IL-2, which is not water soluble or not readily soluble in water at pH 6-8 without such solubilizing ...


9
Qiang Ye, Nandini Katre, Mantripragada Sankaram: Modulation of drug loading in multivescular liposomes. SkyePharma, Fish & Richardson P C, August 22, 2000: US06106858 (29 worldwide citation)

Disclosed is a method for making liposomes, for example multivesicular liposomes (MVLs), containing one or more biologically active agents, wherein the loading of the active agents into the liposomes is modulated by adjusting the osmolarity of the aqueous component into which the agents are dissolve ...


10
Maninder S Hora, Nandini Katre, Kenneth A Laderman: Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers. Cetus Corporation, Philip L McGarrigle, January 7, 1992: US05078997 (25 worldwide citation)

The present invention is a pharmaceutical composition for proteins which are not stably soluble. The preferred protein is IL-2 and the preferred composition includes amino acids, vitamins, polymers, fatty acids or low molecular weight acids.